Propanc Biopharma, Inc.

PPCB

US74346N6022

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 03:45:20 2024-05-17 pm EDT			5-day change	1st Jan Change
0.0007 ^USD	0.00%		-30.00%	-94.17%

Apr. 16	Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	CI
Apr. 16	Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	CI

Propanc Biopharma Inc. Announces the Engagement of Mr. Alan Morell as A Senior Strategic Advisor for the Company

January 10, 2018 at 08:30 am EST

Propanc Biopharma Inc. announced the engagement of Mr. Alan Morell as a Senior Strategic Advisor for the company, focusing on branding, growth strategy and market positioning. Mr. Morell currently serves as Chief Executive Officer of Creative Management Partners LLC.

Latest news about Propanc Biopharma, Inc.

Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	Apr. 16	CI
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	Apr. 15	CI
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding	Feb. 29	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 20	CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	Jan. 16	CI
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding	Dec. 10	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	Dec. 03	CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding	23-10-28	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.04 million in funding	23-10-19	CI
Propanc Biopharma, Inc. announced that it has received $0.0575 million in funding from GS Capital Partners LLC	23-10-15	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.0575 million in funding from GS Capital Partners LLC	23-10-11	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28	CI
Propanc Biopharma, Inc. announced that it has received $0.055 million in funding	23-08-30	CI
Propanc Biopharma, Inc. announced that it has received $0.12 million in funding	23-08-29	CI
Propanc Biopharma, Inc. announced that it has received $0.0725 million in funding from GS Capital Partners LLC	23-08-22	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.055 million in funding	23-08-15	CI
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia	23-08-15	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.12 million in funding	23-08-14	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	23-08-14	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.045 million in funding	23-07-18	CI
Propanc Biopharma, Inc. and an Institutional Investor Enters into a Loan Agreement	23-07-12	CI
Propanc Biopharma, Inc. announced that it has received $0.065 million in funding	23-07-05	CI
Propanc Biopharma, Inc. Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors	23-07-05	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.065 million in funding	23-06-28	CI

Chart Propanc Biopharma, Inc.

Duration

Period

More charts

Company Profile

Propanc Biopharma, Inc. is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on the development of cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROPANC BIOPHARMA, INC.	-94.17%	83.53K
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals